163 related articles for article (PubMed ID: 33692028)
1. Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer.
Hui EP; Ma BBY; Lam WKJ; Chan KCA; Mo F; Ai QH; King AD; Wong CH; Wong KCW; Lam DCM; Tong M; Poon DMC; Li L; Lau TKH; Wong KH; Lo YMD; Chan ATC
Clin Cancer Res; 2021 May; 27(10):2827-2836. PubMed ID: 33692028
[TBL] [Abstract][Full Text] [Related]
2. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma.
Ma B; Hui EP; King A; Leung SF; Kam MK; Mo F; Li L; Wang K; Loong H; Wong A; Chan CM; Chan KCA; Wong SCC; Lo YMD; Chan AT
Br J Cancer; 2018 Apr; 118(8):1051-1055. PubMed ID: 29555989
[TBL] [Abstract][Full Text] [Related]
3. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA.
Wang WY; Lin TY; Twu CW; Tsou HH; Lin PJ; Liu YC; Huang JW; Hsieh HY; Lin JC
Oncotarget; 2016 Jul; 7(27):42608-42616. PubMed ID: 27191654
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels.
Wang WY; Twu CW; Chen HH; Jiang RS; Wu CT; Liang KL; Shih YT; Chen CC; Lin PJ; Liu YC; Lin JC
Cancer; 2013 Mar; 119(5):963-70. PubMed ID: 23065693
[TBL] [Abstract][Full Text] [Related]
5. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Twu CW; Wang WY; Chen CC; Liang KL; Jiang RS; Wu CT; Shih YT; Lin PJ; Liu YC; Lin JC
Int J Radiat Oncol Biol Phys; 2014 May; 89(1):21-9. PubMed ID: 24725686
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma.
Hui EP; Ma BB; Chan KC; Chan CM; Wong CS; To KF; Chan AW; Tung SY; Ng WT; Cheng AC; Lee VH; Chan SL; Loong HH; Kam MK; Leung SF; Ho R; Mo F; Ngan RK; Chan AT
Cancer; 2015 Aug; 121(16):2720-9. PubMed ID: 25946469
[TBL] [Abstract][Full Text] [Related]
7. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
[TBL] [Abstract][Full Text] [Related]
8. Plasma Epstein-Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi.
Westmoreland KD; Montgomery ND; Stanley CC; El-Mallawany NK; Wasswa P; van der Gronde T; Mtete I; Butia M; Itimu S; Chasela M; Mtunda M; Kampani C; Liomba NG; Tomoka T; Dhungel BM; Sanders MK; Krysiak R; Kazembe P; Dittmer DP; Fedoriw Y; Gopal S
Int J Cancer; 2017 Jun; 140(11):2509-2516. PubMed ID: 28268254
[TBL] [Abstract][Full Text] [Related]
9. Plasma Epstein-Barr Viral Deoxyribonucleic Acid Predicts Worse Outcomes in Pediatric Nonmetastatic Nasopharyngeal Carcinoma Patients: An Observational Study of 89 Cases in an Endemic Area.
Shen T; Tang LQ; Gu WG; Luo DH; Chen QY; Li PJ; Mai DM; Mai HQ; Mo HY
Medicine (Baltimore); 2015 Dec; 94(50):e1945. PubMed ID: 26683909
[TBL] [Abstract][Full Text] [Related]
10. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
[TBL] [Abstract][Full Text] [Related]
11. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
12. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
14. Maximal standard uptake values of
Sun XS; Liang YJ; Liu SL; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Tang LQ; Mai HQ
BMC Cancer; 2019 Sep; 19(1):908. PubMed ID: 31511059
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma.
Zhang Y; Li WF; Mao YP; Guo R; Tang LL; Peng H; Sun Y; Liu Q; Chen L; Ma J
Oncotarget; 2016 Feb; 7(8):9576-85. PubMed ID: 26840023
[TBL] [Abstract][Full Text] [Related]
16. Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma.
Lee VH; Kwong DL; Leung TW; Choi CW; Lai V; Ng L; Lam KO; Ng SC; Sze CK; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; Khong PL
Oncotarget; 2017 Jan; 8(3):5292-5308. PubMed ID: 28029657
[TBL] [Abstract][Full Text] [Related]
17. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases.
Zhang W; Chen Y; Chen L; Guo R; Zhou G; Tang L; Mao Y; Li W; Liu X; Du X; Sun Y; Ma J
Medicine (Baltimore); 2015 May; 94(20):e845. PubMed ID: 25997061
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma.
Neo J; Yip PL; Ong EHW; Miao J; Chow WM; Wee JTS; Fong KW; Soong YL; Tan TWK; Tan JSH; Sin SY; Liu J; Loh KS; Tay JK; Ang MK; Tan SH; Lim DWT; Chua MLK
Oral Oncol; 2024 Jan; 148():106655. PubMed ID: 38056062
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
